Market net: 12.39, outstanding market capitalization: 97.19 billion.
Yunnan Watson Biotechnology Co.
1, Yunnan Watson Biotechnology Co., Ltd. was founded on January 16, 2001, the registered office is located in the North District of Hi-Tech Development Zone, Kunming, Yunnan Province, Yunnan University Science and Technology Park, Phase 2, Building A3, 4th Floor, the legal representative of Li Yunchun. The scope of business includes research and development of biological agents (excluding managed commodities); introduction, cooperation and development of biological projects; research and development of technical services for biotechnology-related projects; import and export of biological products, biological drugs and related materials; import and export of technology. (Items subject to approval by law can only be carried out after approval by the relevant authorities) Yunnan Watson Biotechnology Co. has invested in 23 foreign companies.
2. There are more than 580 employees, including more than 110 teams specializing in research and development. Since the company's first self-innovated vaccine product was put into production and listed on the market in September 2007, the operating income and profit have doubled in successive years. The company is the first enterprise in China to have two bacterial polysaccharide protein conjugate vaccine products on the market at the same time. The company has an advanced new vaccine R&D center and pilot base in Kunming National Hi-Tech Zone; modern vaccine production bases in Yuxi Hi-Tech Zone and Jiangsu Taizhou China Pharmaceutical City; and a marketing network covering 29 provinces and cities and more than 2,000 districts and counties in China.
3. In September 2007, the company's first self-developed product "Haemophilus influenzae type b conjugate vaccine" was approved by SFDA and successfully put into production and marketed in Yuxi Vaccine Manufacturing Base, which realized the historical transformation of the company from a research institution to an emerging vaccine enterprise with a complete industrial chain integrating research, production and marketing. In September 2009, the second product of the company with independent intellectual property rights, "Lyophilized Group A and C Meningococcal Polysaccharide Conjugate Vaccine", was also approved for sale. In the next few years, the company will continue to introduce to the market a series of vaccine products with excellent structure and great market prospects.
4. On May 11, 2020, Watson Biologicals announced that it had signed a Technology Development Cooperation Agreement with Abbott Bio. ***Together, they will cooperate to carry out preclinical research, clinical trials, and implement commercial production of mRNA New Crown Vaccine.
5. On July 21, 2021, the domestic mRNA New Crown Vaccine, which is a collaboration between Watson Biologicals and Abbot Biologicals, will undergo Phase III clinical trials in China.